Skip to main content
Danelle James, MD, Oncology, La Jolla, CA

DanelleFrancesJamesMD

Oncology La Jolla, CA

Hematologic Oncology

Physician

Are you Dr. James?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 41 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

  • Office

    3855 Health Sciences Dr # 820
    Ucsd Moore's Cancer Center
    La Jolla, CA 92093
    Phone+1 858-822-7894
    Fax+1 858-534-5620
  • Is this information wrong?

Summary

  • Dr. Danelle James, MD is an oncologist in La Jolla, California. She is currently licensed to practice medicine in California.

Education & Training

  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterResidency, Internal Medicine, 2002 - 2005
  • Pennsylvania State University College of Medicine
    Pennsylvania State University College of MedicineClass of 2002

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - 2025

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Results from IMBRUVICA® (Ibrutinib) RESONATE-2 Study Provide up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
    Results from IMBRUVICA® (Ibrutinib) RESONATE-2 Study Provide up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)June 4th, 2021
  • “Collaboration Is Key.” with Danelle James
    “Collaboration Is Key.” with Danelle JamesDecember 9th, 2020
  • AbbVie Submits Supplemental New Drug Application to U.S. FDA for IMBRUVICA® (Ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
    AbbVie Submits Supplemental New Drug Application to U.S. FDA for IMBRUVICA® (Ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic LeukemiaDecember 23rd, 2019
  • Join now to see all

Professional Memberships